Clinical trial · Interventional
Efficacy and Safety of Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion
Efficacy and Safety of Intrapleural Bevacizumab Versus Pulvis Talci in Malignant Pleural Effusion, A Randomized, Multicenter Study
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Patients with Malignant pleural effusion can be diagnosis advanced cancer. Currently recognized as the most reliable method to control malignant pleural effusion is pleural fixed or thoracic catheter drainage. The most effective pleural fixed agent is pulvis talci, but there are about 30% relapse rate. Thoracic drainage can lead to some complications, such as chest infections, catheter migration and blockage etc. The investigators need a reliable methods to solve dyspnea and other symptoms caused by malignant pleural effusion, and improve quality of life. The purpose of this study was to determine the efficacy and Safety of intrapleural Bevacizumab versus pulvis talci as treatment for malignant pleural effusions (MPE) in patients.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Malignant Pleural Effusion | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bevacizumab | Drug | Bevacizumab | ALIAS |
| Pulvis talci | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Bevacizumab
- description
- Bevacizumab200mg by intrapleural administration
- interventionNames
- Drug: Bevacizumab
- type
- ACTIVE_COMPARATOR
- label
- Pulvis talci
- description
- Pulvis talci 4g by intrapleural administration
- interventionNames
- Drug: Pulvis talci
Primary outcomes (1)
- measure
- Changes in chest drainage
- timeFrame
- up to 3months
- description
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Diagnose malignant pleural effusions by: * Diagnose malignant pleural neoplasms by histopathology * Recurrent pleural effusion, Histologically or cytologically confirmed diagnosis of cancer 2. Written informed consent Exclusion Criteria: 1. \<18years of age 2. Expected survival \<3 months 3. Chest infection, chylothorax, pleurodesis or ipsilateral lung surgery once 4. Planned chemotherapy 5. Pregnancy or breast-feeding (women of child-bearing potential) 6. Not signed informed consent or non-compliance with treatment protocols
References
Publications (0)
Data not yet available